Automate Your Wheel Strategy on ABT
With Tiblio's Option Bot, you can configure your own wheel strategy including ABT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABT
- Rev/Share 25.0675
- Book/Share 29.3105
- PB 4.3052
- Debt/Equity 0.254
- CurrentRatio 1.7034
- ROIC 0.1879
- MktCap 218309899422.0
- FreeCF/Share 3.9548
- PFCF 31.5614
- PE 15.695
- Debt/Assets 0.1537
- DivYield 0.0188
- ROE 0.2824
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ABT | The Benchmark Company | -- | Buy | -- | $145 | Oct. 10, 2025 |
| Upgrade | ABT | Jefferies | Hold | Buy | -- | $145 | July 18, 2025 |
| Initiation | ABT | Leerink Partners | -- | Market Perform | -- | $143 | June 16, 2025 |
| Initiation | ABT | Oppenheimer | -- | Outperform | -- | $130 | Oct. 8, 2024 |
| Initiation | ABT | Piper Sandler | -- | Overweight | -- | $131 | Sept. 19, 2024 |
News
Abbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial Fibrillation
Published: December 22, 2025 by: PRNewsWire
Sentiment: Neutral
Abbott's Volt™ PFA System, the latest generation of cardiac ablation technology, is designed for people battling heart rhythm disorders such as atrial fibrillation (AFib) Pulsed field ablation – or PFA – is a minimally invasive procedure that uses high-energy electrical pulses in targeted areas of the heart to treat irregular heart rhythms Abbott's Volt PFA System is an all-in-one product that is clinically proven to simplify the treatment of AFib that is gentler on the heart, has shorter procedure times and supports better recovery and long-term results ABBOTT PARK, Ill., Dec. 22, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced …
Read More
Abbott's Amplatzer Piccolo™ Delivery System Receives FDA Clearance and CE Mark to Optimize Procedures for Premature Babies With a Hole in the Heart
Published: December 18, 2025 by: PRNewsWire
Sentiment: Neutral
First and only delivery system designed specifically for premature infants with a patent ductus arteriosus (PDA), a life-threatening opening in their heart New delivery system enables precise placement of Abbott's Amplatzer Piccolo Occluder in the tiniest babies A PDA requiring treatment is present in approximately 20% of premature infants1 ABBOTT PARK, Ill., Dec. 18, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its Amplatzer Piccolo™ Delivery System, which is used with the company's Amplatzer Piccolo Occluder.
Read More
PBH vs. ABT: Which Stock Should Value Investors Buy Now?
Published: December 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Is Trending Stock Abbott Laboratories (ABT) a Buy Now?
Published: December 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Abbott Gains From Lingo CGM's Expansion on Android Platform
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Positive
ABT expands its Lingo biowearable to Android, broadening access to real-time glucose tracking and pushing continuous monitoring into mainstream wellness.
Read More
Abbott increases quarterly dividend for 54th consecutive year
Published: December 12, 2025 by: PRNewsWire
Sentiment: Neutral
Quarterly dividend increased by 6.8% Quarterly dividend payout has increased more than 70% since 2020 408th consecutive quarterly dividend to be paid by Abbott since 1924 ABBOTT PARK, Ill., Dec. 12, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend to 63 cents per share, an increase of 6.8%.
Read More
Muscles, the New Flex: Abbott Launches Two New Ensure® Max Protein Shakes to Tap into Growing Muscle Health Movement
Published: December 04, 2025 by: PRNewsWire
Sentiment: Neutral
Aging, nutrition and lifestyle affect muscles, especially after age 40. That's why Matt Ryan, former professional quarterback and MVP, is teaming up with Abbott to drive muscle health awareness with two new Ensure Max Protein shakes Ensure Max Protein 42g: For physically active adults, this new shake delivers 42 grams of complete protein to help build muscle tissue alongside resistance training with 23 vitamins and minerals and two key electrolytes to support muscle function Ensure Max Protein 2 in 1 Muscle Support: For older adults who need help maintaining muscle as they age, this shake has 30 grams of protein …
Read More
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Published: December 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Read More
PBH or ABT: Which Is the Better Value Stock Right Now?
Published: December 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Abbott (ABT). But which of these two stocks is more attractive to value investors?
Read More
Abbott to buy Exact Sciences for $21B in cancer diagnostics reach push
Published: November 20, 2025 by: Proactive Investors
Sentiment: Positive
Abbott Laboratories (NYSE:ABT) on Thursday announced a definitive agreement to acquire cancer diagnostics company Exact Sciences (NASDAQ:EXAS) in a deal valued at approximately $21 billion. Exact Sciences, known for its noninvasive colorectal cancer screening test Cologuard and multi-cancer early detection test Cancerguard, reported projected revenue of more than $3 billion this year, with high-teens organic growth.
Read More
Abbott is weighing takeover of Exact Sciences, Bloomberg News reports
Published: November 19, 2025 by: Reuters
Sentiment: Positive
Medical device maker Abbott Laboratories is nearing a potential takeover of cancer test maker Exact Sciences Corp , Bloomberg News reported on Wednesday, citing people familiar with the matter.
Read More
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Published: November 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Read More
Why Is Abbott (ABT) Up 1.3% Since Last Earnings Report?
Published: November 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) reported earnings 30 days ago. What's next for the stock?
Read More
Goldman Sachs Says US Stocks Could Lag for 10 Years: 5 Strong Buy Value Dividend Ideas
Published: November 13, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Goldman Sachs has projected that U.S. stocks will deliver lackluster returns over the next decade primarily due to two key factors: extreme market concentration and elevated valuations.
Read More
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Abbott Showcases World's First Dual Chamber Leadless Pacemaker in National Media Tour Featuring Patient Story with YourUpdateTV
Published: October 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
Boston Teacher Shares Life-Changing Experience with Breakthrough Dual Chamber Leadless Pacemaker During Nationwide Interviews in Conjunction with D S Simon Media Boston Teacher Shares Life-Changing Experience with Breakthrough Dual Chamber Leadless Pacemaker During Nationwide Interviews in Conjunction with D S Simon Media
Read More
HOLX vs. ABT: Which Medical Technology Stock Is the Better Investment?
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Hologic's $18.3B buyout deal and Abbott's strong growth across key segments set up a close contest for MedTech investors.
Read More
Goldman Sachs Still Says Sell-Off Coming – 5 Safe Conviction List Picks
Published: October 26, 2025 by: 24/7 Wall Street
Sentiment: Positive
Founded in 1869, Goldman Sachs is the world's second-largest investment bank by revenue and is ranked 55th on the Fortune 500 list of the largest United States corporations by total revenue.
Read More
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Abbott Q3 Earnings Review: Tariff, Diagnostics Cap Near-Term Gains
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott posts strong Q3 growth across key segments, but tariff pressures and weak Diagnostics weigh on near-term momentum.
Read More
Abbott Laboratories' October Price Plunge Is a Signal to Buy
Published: October 17, 2025 by: MarketBeat
Sentiment: Negative
Abbott Laboratories' NYSE: ABT October price plunge is a signal to buy, as analyst and institutional trends suggest they, too, will be buying the stock. Analyst trends revealed by MarketBeat data include increasing coverage with newly initiated ratings appearing within days of the Q3 earnings release.
Read More
Goldman Sachs 4 New Conviction List Stocks Offer Dividends and Growth
Published: October 17, 2025 by: 24/7 Wall Street
Sentiment: Positive
The Goldman Sachs Conviction List is a curated list of stocks that the firm's research team believes have a high likelihood of outperforming the market.
Read More
Abbott Laboratories Q3 2025 Earnings: Stable Growth Amid Tariff And China Headwinds
Published: October 16, 2025 by: Seeking Alpha
Sentiment: Negative
Abbott Laboratories delivered solid Q3 2025 results, with diversified growth across medical devices, nutrition, and branded generics offsetting diagnostics weakness. ABT's international presence and exposure to emerging markets drive structural growth, while its broad portfolio provides resilience amid global economic volatility. Tariffs and China remain key risks, but ABT's flexible supply chain and reduced China exposure help limit downside, with management actively shifting focus to other regions.
Read More
Gold Gains Over 1%; Abbott Shares Fall After Q3 Results
Published: October 15, 2025 by: Benzinga
Sentiment: Neutral
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Wednesday.
Read More
Abbott Laboratories (ABT) Q3 2025 Earnings Call Transcript
Published: October 15, 2025 by: Seeking Alpha
Sentiment: Neutral
Abbott Laboratories (NYSE:ABT ) Q3 2025 Earnings Call October 15, 2025 9:00 AM EDT Company Participants Michael Comilla - Vice President of Investor Relations. Robert Ford - Chairman of the Board, President & CEO Philip Boudreau - CFO & Executive VP of Finance Conference Call Participants Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Joshua Jennings - TD Cowen, Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Danielle Antalffy - UBS Investment Bank, Research Division Joanne Wuensch - …
Read More
NVST or ABT: Which Is the Better Value Stock Right Now?
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Products stocks are likely familiar with Envista (NVST) and Abbott (ABT). But which of these two stocks is more attractive to value investors?
Read More
Abbott's Q3 Earnings Meet Estimates, Revenues Up Y/Y, Stock Climbs
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive
ABT's Q3 earnings meet expectations as revenues climb 6.9% year over year, driven by double-digit gains in Medical Devices.
Read More
Here's What Key Metrics Tell Us About Abbott (ABT) Q3 Earnings
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Abbott (ABT) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Abbott Laboratories posts steady sales growth in Q3, reaffirms full-year guidance
Published: October 15, 2025 by: Proactive Investors
Sentiment: Positive
Abbott Laboratories (NYSE:ABT) reported steady growth in the third quarter, with sales rising 6.9% to $11.37 billion, slightly below estimates of $11.4 billion, and adjusted earnings per share matching expectations at $1.30. The company's results were driven by broad-based strength across Abbott's medical devices and diagnostics businesses, even as COVID-19 testing-related revenue continued to normalize.
Read More
Abbott (ABT) Q3 Earnings Meet Estimates
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) came out with quarterly earnings of $1.3 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $1.21 per share a year ago.
Read More
About Abbott Laboratories (ABT)
- IPO Date 1980-03-17
- Website https://www.abbott.com
- Industry Medical - Devices
- CEO Robert Ford
- Employees 114000